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Abstract.12
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder and is the most common cause of dementia worldwide.
Cumulative data suggests that neuroinflammation plays a prominent and early role in AD, and there is compelling data
from different research groups of age-associated dysregulation of the neuroimmune system. From the clinical point of view,
despite clinical resemblance and neuropathological findings, there are important differences between the group of patients
with sporadic early-onset (<65 years old) and late-onset AD (>65 years old). Thus, it seems important to understand the
age-dependent relationship between neuroinflammation and the underlying biology of AD in order to identify potential expla-
nations for clinical heterogeneity, interpret biomarkers, and promote the best treatment to different clinical AD phenotypes.
The study of the delicate balance between pro-inflammatory or anti-inflammatory sides of immune players in the different
ages of onset of AD would be important to understand treatment efficacy in clinical trials and eventually, not only direct
treatment to early disease stages, but also the possibility of establishing different treatment approaches depending on the age
of the patient. In this review, we would like to summarize what is currently known about the interplay between “normal” age
associated inflammatory changes and AD pathological mechanisms, and also the potential differences between early-onset
and late-onset AD taking into account the age-related neuroimmune background at disease onset.
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INTRODUCTION27
Alzheimer’s disease (AD) is a chronic neu-28
rodegenerative disorder and is the most common
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cause of dementia worldwide. The two major neu- 29
ropathological hallmarks of the disease are senile 30
plaques, which are mainly composed of extracellu- 31
lar deposits of amyloid- (A) and neurofibrillary 32
tangles, which consist of intracellular aggregates 33
of aberrantly phosphorylated tau protein. This is 34
accompanied by neuronal and synaptic loss, den- 35
dritic and axonal changes, and inflammatory reaction 36
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lesions [1, 2]. Cumulative data suggests that neu-37
roinflammation plays a prominent and early role38
in AD [3–8]. Microglia cells are the predominant39
resident immune cells in the central nervous sys-40
tem (CNS) [9]. Recently, some studies highlighted41
the biological process of age-related changes associ-42
ated with microglial cells [10–12] and suggest that43
microglial senescence can be directly associated to44
neurofibrillary degeneration [13]. From the clini-45
cal point of view, despite clinical resemblance and46
neuropathological findings, there are important dif-47
ferences between the group of patients with sporadic48
early-onset (<65 years old, EOAD) and late-onset AD49
(>65 years old, LOAD). Thus, it seems important to50
understand the age-dependent relationship between51
neuroinflammation and the underlying biology of AD52
in order to identify potential explanations for clinical53
heterogeneity, interpret biomarkers, and promote the54
best treatment to different clinical AD phenotypes.55
In this article, we will discuss the current56
knowledge regarding the interplay between “nor-57
mal” age associated inflammatory changes and AD58
pathological mechanisms. In addition, we will dis-59
cuss the potential differences between EOAD and60
LOAD taking into account the age-related neuroim-61
mune background at disease onset. We will give62
particular emphasis to microglia due to their predom-63
inant role in the immunological process within the64
CNS.65
BRAIN IMMUNE SYSTEM66
Microglia are the resident immune cells of the CNS67
and considered the tissue-resident macrophages.68
These cells were first described by Nissl in 1899,69
who distinguished microglia from other neural cells70
based on the shape and their nuclei [14]. Microglia71
cells arise from myeloid precursors and constitute72
an autonomous population distinct from the periph-73
eral circulating mononuclear phagocytes [15]. These74
cells account for up to 16% of total cell CNS pop-75
ulation and this is dependent on the brain region76
[9]. There is limited replication and turnover of77
microglia, suggesting that microglia are a very long-78
lived and stable cell population [9, 12]. Microglia79
can provide several macrophage-related activities80
that provide an innate immune response as the first81
and main form of active immune defense in the82
brain [9]. The term microglial activation encloses83
the process where microglia change shape, molec-84
ular signature, and cellular physiology in order to85
respond to injury or disease [16]. Resting microglia 86
are characterized by a small cell body, highly ram- 87
ified processes with weak expression of associated 88
cell surface marker antigens [17]. In contrast, acti- 89
vated microglia display shortened and extensively 90
branched processes and hypertrophy of cell body 91
[18]. The definition of resting microglia does not 92
mean a passive spectator in the healthy adult CNS. In 93
vivo two-photon microscopy imaging studies showed 94
that microglia survey the brain parenchyma by con- 95
stantly extending and retracting their processes, and 96
react rapidly to brain injury or insult, and are more 97
properly termed “surveillant” [19–21]. The functions 98
of microglia in the normal healthy brain beyond 99
immune surveillance are unclear, but recently more 100
sophisticated functions were described such as par- 101
ticipating actively in the maintenance and plasticity 102
of neuronal circuits and contributing to the protection 103
and remodeling of synapses [22, 23]. 104
Microglial activation states have been classically 105
described as activated (M1) or alternatively activated 106
(M2) [24]. The M1 phenotype is characterized by 107
production of proinflammatory cytokines, such as IL- 108
1, tumor necrosis factor alpha (TNF), and IFN-, 109
whereas in the M2 phenotype microglia secrete anti- 110
inflammatory cytokines, such as IL-4, IL-10, and 111
transforming growth factor-, which downregulate 112
inflammation and promote tissue remodeling/repair 113
and angiogenesis [25]. However, this categorizing 114
system relays on peripheral macrophages studies, 115
which do not recapitulate all microglial functions and 116
is likely an oversimplification [21]. 117
The second type of neuroimmune cells is the 118
perivascular macrophages [26]. They seem to be 119
derived from circulating macrophages, and are able 120
to perform all the known functions of periph- 121
eral macrophages; they undergo complete turnover 122
approximately every 3 months [27, 28]. Finally, the 123
circulating blood monocyte can enter the CNS, but 124
it is not clear how often it happens under non- 125
inflammatory conditions. In conditions of disrupted 126
blood-brain barrier, and when properly stimulated, 127
they can differentiate into microglia-like cells or 128
perivascular macrophages morphologically and phe- 129
notypically [26]. 130
Astrocytes are the most abundant glial cells in 131
the CNS and their function is critical for the sup- 132
port of neuronal homeostasis. The term astrogliosis 133
describes a wide range of both molecular and func- 134
tional changes in astrocytes aimed to neuroprotection 135
and repair of injured neural tissue [29, 30]. Recently it 136
has been shown that that reactive astrogliosis and glial 137
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scar formation play essential roles in regulating CNS138
inflammation [29]. Reactive astrocytes in response139
to different kinds of insult can produce molecules140
with either pro- or anti-inflammatory potential. Addi-141
tionally, reactive astrocytes can exert both pro- and142
anti-inflammatory effects on microglia [31, 32].143
NEUROINFLAMMATION IN BRAIN144
AGING145
There is clinical and experimental evidence that146
neuroinflammation in the aged brain is characterized147
by a shift toward a pro-inflammatory state [9, 33].148
In vivo imaging studies using 11-C-R-PK1195 PET149
ligand, which is upregulated in activated microglia150
cells, showed an increase in the specific binding with151
age in several cortical and subcortical structures, indi-152
cating that activated microglia gradually appear in153
the aging human brain [34]. In parallel, age senes-154
cent alterations can contribute to a dysfunctional155
microglia [12, 35, 36]. In the next paragraphs, we156
will address these apparent competitive perspectives157
of age-related neuroinflammation.158
Inflammation in the brain is defined by upregulated159
astrocyte and microglial cell reactivity in association160
with increased levels of circulating cytokines such161
as TNF, IL-1, and IFN- [37–39]. With aging,162
microglia phenotype shifts progressively toward the163
activated form, together with enhanced sensitivity to164
inflammatory stimuli (priming phenomena) [9, 40].165
In normal human brain aging, microglia is character-166
ized by upregulation of glial activation markers such167
as IL-1 [41] and major histocompatibility complex168
II (MHC II) [42]. MHC II is important because it is169
conserved across species and is interpreted to indicate170
microglial priming [9]. There is compelling evidence171
from different research groups and aging models, that172
following different types of challenge (bacteria, virus,173
stress, surgical intervention), aged animals exhibited174
a clear and exaggerated neuroinflammatory response,175
when compared to young adult animals [33, 43–46].176
These studies provided evidence that during lifespan,177
episodes of systemic inflammation and cytokine stim-178
ulation can “instruct” microglia and increase their179
reactivity [23, 33]. Interestingly, some of these sen-180
sitized neuroinflammatory responses are specific to181
the hippocampal formation, which is important for182
memory function [33]. Microglia from the aged CNS183
could be described as hyper-vigilant to disturbances184
in central homeostasis with less capability of shifting185
among functional states.186
Proteins expressed in CNS microenvironment, 187
which are known to inhibit microglia activation or 188
pro-inflammatory immune responses, were impli- 189
cated in the mechanism how microglia becomes 190
chronically sensitized during normal aging [47]. In 191
fact, some lines of research describe various proteins 192
that activate anti-inflammatory signals following lig- 193
and receptor interactions [48], particularly CD200 194
[49–51] and fractalkine (CX3CL1) [51–53]; interest- 195
ingly, both are preferentially expressed in neurons. 196
These proteins inhibit microglia through their cog- 197
nate receptor, which is expressed predominantly in 198
myelomonocytic cell types. During aging, the expres- 199
sion of levels of these ligands decreases concurrently 200
with increases in microglial activation status. More 201
recently, another line of research suggests that sig- 202
nificant and prolonged elevation in hippocampal 203
corticosterone (the endogenous glucocorticoid in 204
rodents) leads to microglial priming [51]. However, 205
the simplistic view that aging CNS shifts microglial 206
polarization from alternative M2 state to the clas- 207
sical, proinflammatory state, should be interpreted 208
cautiously because many studies found that both 209
M1 markers and M2 markers are increased in aged 210
mice [12]. For example, active microglia from aged 211
mice actually had higher levels of IL-10 production 212
(an anti-inflammatory cytokine) than those of adult 213
mice and lower expression of TGF (an inflamma- 214
tory cytokine) [54]. In this case, the maintenance 215
of inflammatory response could be attributed to an 216
impaired response to IL-10 in the aged brain [9]. Fur- 217
thermore, primed microglia phenomena have been 218
described mainly in mouse models [9, 55], and less 219
in human brain research [56]. More recently, research 220
studies showed that the cerebrospinal fluid (CSF) 221
levels of YKL-40 (a microglial marker) increase in 222
normal aging [57–59]. 223
Together with this perspective that microglia 224
becomes primed and more reactive with age, others 225
showed that microglia becomes senescent and less 226
reactive with age [10, 11, 13]. In the healthy young 227
CNS, microglia have a typical ramified morphology 228
and are distributed throughout the neural parenchyma 229
in a “space-filling” manner [60]. Due to the pro- 230
longed lifespan of CNS microglia, they are more 231
susceptible to accumulate aging-related changes [61], 232
such as in the distribution, morphology, and behav- 233
ior [12, 60] (Table 1). Many microglial cells in the 234
aged brain show dystrophic features indicative of age- 235
related alterations. This dystrophic microglia have 236
de-ramification or decrease arborization of their pro- 237
cesses, loss of finely branched cytoplasmic process, 238
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Table 1
Summary of principal changes associated to microglial aging (adapted from Wong [60] and Wyss-Coray [6])
Changes in aged microglia
Changes in microglial distribution
Replicative senescence (reduced mitotic activity in response to CNS injuries)
Decreases in regularity in distribution
Changes in morphology
Decrease in individual microglial ramification (dendritic arbor area, branching, and total process length)
Appearance of morphological changes suggestive of increase activation state
(shortened and extensively branched processes and hypertrophy of cell body)
Appearance of dystrophic microglia (deramified, fragmented, or tortuous processes,
cytoplasmic beading/spheroid formation)
Changes in microglial dynamic behavior and function
Decrease in the motility and migration process
Changes in intercellular signaling and marker expression (MHC II, CD11b)
Impaired phagocytosis
Impaired proteostasis
cytoplasmic beading/spheroid formation, and short-239
ened and twisted cytoplasmic processes, and in some240
instances there is partial or complete cytoplasmic241
fragmentation [38]. The meaning of these morpho-242
logical changes or why they happen is still to be243
understood.244
Age-related changes were also described in astro-245
cytes, particularly emphasizing that aged astrocytes246
show characteristics of the senescence-associated247
secretory phenotype, which involves increased secre-248
tion of inflammatory components [62].249
In summary, aged microglia are primed with exag-250
gerated and prolonged responses to inflammatory251
stimuli and also display dysfunctional dystrophic age252
associated features. Yet, it is still to be determined253
if microglia activation is the cause of neurodegen-254
eration or a secondary reactive (beneficial) process;255
or if the neurodegeneration is actually secondary256
to microglia senescence and associated loss of257
microglial protection.258
NEUROINFLAMMATION IN259
ALZHEIMER’S DISEASE260
After two decades of the amyloid cascade hypothe-261
ses proposed by Hardy and Higgins [63], multiple262
lines of research still support the A aggregation as263
the critical step that initiates AD pathology. How-264
ever, despite required, it seems that A aggregation265
is not sufficient for the development of the neu-266
ropathological and clinical syndrome of AD [64].267
Several research studies report links between AD and268
genes regulating immunity as well as the expres-269
sion of immune factors in blood, CSF, and brain270
tissue [8, 65–68]. There is compelling data that neu-271
roinflammation in AD is not a passive mechanism272
activated by senile plaques and neurofibrillary tan- 273
gles, but instead contributes, as much or even more, 274
to pathogenesis as do plaques and tangles [65, 68, 275
69]. Epidemiological studies indicate that systemic 276
markers of the innate immunity are risk factors of 277
LOAD [70–73] and more recently, inflammation 278
in AD gained strong support from genome-wide 279
association studies that identified genes involved in 280
inflammation that are associated with increased risk 281
of developing AD [74], including TREM2 [75, 76] 282
and CD33 [77, 78]. Prospective cohorts’ studies 283
suggested that elevations in inflammatory media- 284
tors may be present years before clinical disease 285
onset [70, 79, 80]. However, other longitudinal stud- 286
ies did not report associations between inflammation 287
and AD risk [81, 82]. Furthermore, non-steroidal 288
anti-inflammatory drug (NSAID) epidemiology and 289
clinical trials showed mostly negative results, play- 290
ing against the importance of inflammation in AD 291
pathogenesis. However, these disappointing results 292
are no surprising taking into account that normal 293
physiological cytokine regulation of glia activation 294
and microglial phenotypes are highly dependent of 295
the context and the disease stage [65]. More recently, 296
studies have consistently found an increase in CSF 297
YKL-40 levels in AD. They also found a correla- 298
tion between CSF YKL-40 levels with markers of 299
neurodegeneration, such as tau, and with at-risk 4 300
carriers during mid middle age [57–59]. 301
Neuropathological studies have shown the pres- 302
ence of a broad variety of inflammation-related 303
proteins (complement factors, acute-phase proteins, 304
proinflammatory cytokines) and clusters of activated 305
microglia around amyloid plaques (Fig. 1) in AD sub- 306
jects and also AD mice models [8], and these findings 307
have been implicated in the neurodegeneration pro- 308
cess [4, 83]. Neuropathological studies also showed 309
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Fig. 1. Alzheimer’s disease neuropathology. A) Senile plaques and globose diffuse deposits demonstrated with anti-A antibody (M 0804,
Dako). B) Neurofibrillary tangles demonstrated by phosphorylated tau protein immunohistochemistry (PHF-Tau; AT8, Thermo Scientific).
C) Diffuse distribution of activated microglia in the cortex with clustering within and around amyloid plaques. D) Higher magnification
of amyloid plaque with activated microglial in the CA4 region of the hippocampus (C and D: CD68 immunohistochemistry; PGM1 clone,
Dako).
that the neuroinflammatory response in the neocor-310
tex is present in the early stages of AD pathology and311
precedes the late stage, tau-related pathology [84].312
Furthermore, microglial activation has been shown313
to progress with the clinical stage of dementia, with314
neuropathological stage of disease severity, and with315
stage of progression of A plaques [67, 85, 86].316
In vivo imaging studies, using 11-C-R-PK1195 PET317
ligand, showed that activated microglia accumulate318
near the amyloid plaque pathology, and that activated319
microglia burden correlates with cognitive decline320
[87].321
The pathological accumulation of A is consid-322
ered the key factor that drives neuroinflammation323
responses in AD [65]. The chronic deposition of324
A stimulates the persistent activation of microglial325
cells in AD [88]. Microglia undergoes a progres-326
sive switch from a neuroprotective M2 status to a327
classically activated phenotype M1, characterized328
by production of proinflammatory cytokines [89].329
The persistent microglia activation and consequently330
microglia-derived cytokine overexpression, caused331
by continuous formation of A and positive feedback332
loops between inflammation and amyloid- protein333
precursor processing, can increase A production 334
and decrease A clearance, ultimately causing neu- 335
ronal damage [65, 86, 89]. In addition, ongoing 336
exposure to A, chemokines, cytokines, and other 337
inflammatory mediators can be responsible for the 338
functional impairment of microglial cells seen at 339
plaque sites [11, 90] and thus impede the protec- 340
tive role of microglia in A clearance [91]. Recently, 341
Kim et al. [92] showed that soluble A oligomers 342
impair synaptic plasticity and cause synaptic loss in 343
mouse AD models and brains of AD patients bind- 344
ing to the murine PirB (paired immunoglobulin-like 345
receptor B) and its human ortholog LilrB2 (leu- 346
cocyte immunoglobulin-like receptor B2) receptors, 347
respectively. The PirB receptor was first described 348
exclusively in the immune system but is now know 349
to be expressed by neurons. 350
Microglia can have different roles and effects 351
depending on the particular disease stage and which 352
brain region is affected in each model [65]. AD 353
mouse models studies showed that in younger ages, 354
together with the appearance of the first A plaques, 355
the microglia is activated toward the alternative 356
state and at older ages, together with the increased 357
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accumulation of extracellular oligomeric A, there358
is a widespread microglial activation toward the clas-359
sic phenotype [93]. Recently, Sudduth et al. described360
that in the early-stage AD brains there is an apparent361
polarization toward either M1 or M2 brain inflam-362
matory states [94]. The M2 polarized group had363
great number of neuritic plaques, eventually reflect-364
ing disease progression. The heterogeneity found in365
the early stage AD can influence the response to366
therapeutic agents that act on immune system and367
inflammation [94]. The neuropathological study of368
AD patients that had undergone active A vaccina-369
tion as part of the AN1792 trial showed significantly370
reduced levels of A and reduction of aggregated371
tau in neural processes (not in neurofibrillary tan-372
gles), and, although there was no difference on total373
microglial load, there were reduced levels of a range374
of activated microglial species when compared to375
patients who died from AD without treatment [95,376
96]. These findings suggest that downregulation of377
microglial activation through A immunotherapy378
possibly reduces the inflammatory component of the379
neurodegeneration of AD [95]. However, a different380
line of research supports that aging-related microglial381
degeneration and loss of microglial neuroprotection382
rather than microglial activation contributes to the383
onset of sporadic AD [11]. A role for peripheral-384
derived macrophage cells in AD pathophysiology385
have recently come under attention [97]. There is386
extensive evidence that blood-derived monocytes can387
phagocytose A [98] and that these cells can be388
recruited to the AD brain, albeit in low numbers [99].389
Reactive astrocytes tend to accumulate around fib-390
rillar amyloid plaques [100]. Similar to microglia,391
astrocytes release cytokines and other potentially392
cytotoxic molecules after exposure to A thus aggra-393
vating the neuroinflammatory response [65]. Glial394
cell activation can be an early event in AD process,395
even preceding A deposition. Recently, Rodriguez-396
Vieitez and colleagues [101], using a PET tracer397
for astrocytes (11C-deuterium-L-deprenyl), showed398
prominent initially high and then declining astrocy-399
tosis in autosomal dominant AD carriers, contrasting400
with the increasing A plaque load during disease401
progression. This study provided in vivo evidence that402
astrocyte activation is a very early feature of, at least403
familial, AD pathology [101]. Other lines of research404
have linked senescent astrocytes to the increase risk405
of sporadic AD [102].406
In summary, the role of microglia remains con-407
troversial in AD pathogenesis and the question408
of whether activated microglia aids in promoting409
clearance of toxic A species or if their proinflamma- 410
tory profile exacerbates pathology is currently a topic 411
of debate [103]. Although there is broad evidence of 412
a large immune response component in AD, the issue 413
of which activation phenotype affects the onset or 414
progression of the disease and, consequently, which 415
should be the therapeutic target remains to be deter- 416
mined [104]. Furthermore, the questions regarding 417
the role of excessive astrogliosis or astrocyte senes- 418
cent loss of function in AD pathogenesis remains to 419
be solved [100]. 420
EARLY AND LATE-ONSET 421
ALZHEIMER’S DISEASE 422
Regardless of the clinical resemblance and 423
neuropathological findings, important differences 424
between EOAD and LOAD patients have been 425
reported. The separation of EOAD from LOAD at 65 426
years old is a conventional cutoff point indicative of 427
a sociological partition in terms of employment and 428
retirement, but there is no specific biological signifi- 429
cance to use this specific age, and there is a range of 430
disease features that do not respect this arbitrary divi- 431
sion [105, 106]. However, this arbitrary cutoff point 432
has been used widely by different research groups 433
and allowed the uniform study of AD patients with 434
different ages of onset. 435
Clinical presentation 436
Whether age of onset defines the clinical presen- 437
tation of AD has been a matter of debate for decades 438
and reports on this issue are often contradictory. 439
Nonetheless, some differences have been consis- 440
tently recognized. Earlier onset is associated with a 441
worse prognosis and a faster progression. Younger- 442
onset patients have comparatively worst outcomes 443
in the Mini-Mental State Examination at baseline, 444
show a steeper cognitive and functional decline, and 445
seem to have higher mortality risks when compared 446
to older-onset patients [107–109]. In addition, dif- 447
ferent patterns of cognitive deficits are apparent; 448
non-amnestic presentations are more often found in 449
early-onset disease, described in 33–64% of EOAD 450
compared to 6–12.5% of LOAD patients [105, 110]. 451
Earlier neuropsychological studies have shown 452
that younger patients have more language disability 453
when compared to older-onset patients [111–113]. 454
The risk of having language difficulties detected by 455
caregivers has also been shown to nearly duplicate 456
for each 10-year decrease in AD patients’ age [114]. 457
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Other groups have recognized a greater impairment in458
measures of attention, praxis, and visuo-contruction459
tasks in EOAD [115–117]. On the other hand, LOAD460
patients seem to consistently have preferential mem-461
ory involvement [118–120]. To explore the relation462
between this clinical duality and pathologic features,463
Murray et al. [121] divided a cohort of AD patients464
into “hippocampal sparing”, “limbic predominant”,465
and “typical AD” according to neurofibrillary pathol-466
ogy distribution. They have shown that a younger age467
of onset (mean 63 years) was associated with greater468
neurofibrillary tangle burden in cortical association469
areas and that older age (mean 76 years) was more470
often associated with limbic predominant pathology.471
The hippocampal sparing group had greater preva-472
lence of atypical presentations and a faster cognitive473
decline, similar to what has been described in EOAD.474
Seizures and extrapyramidal features seem to be475
more frequent in EOAD [111, 122]. There are con-476
tradictory reports in other symptoms in both groups.477
For example, there are reports of higher anxiety lev-478
els in EOAD [123], while others have shown greater479
neuropsychiatric and behavioral symptoms in LOAD,480
including anxiety, depression, agitation, hallucina-481
tions, and delusions [124, 125].482
Limited research has been reported into sex differ-483
ences in brain aging, particularly neuroinflammation484
process. However, gender effect is an interesting485
issue due to the differences of the neuroendocrine486
milieu and its possible relation to inflammation cas-487
cades (particularly steroid-related pathways). The488
dynamic change in hormonal status in women during489
the menopause transition may promote a dysregula-490
tion of cellular processes involved in hypothalamic-491
pituitary-adrenal axis and thus have potential implica-492
tions on stress-mediated neurotoxicity [126]. It is also493
important to recognize the importance of immunolog-494
ical differences in males and females within the CNS495
at different development time points and their possi-496
ble relevance for the susceptibility in the development497
of neurological conditions later in life [127]. A recent498
work in mice by Mangold and colleagues showed a499
greater induction of MHC class I components and500
receptors with aging with this finding being greater501
in females than in males [128]. However, despite the502
prevalence of AD being greater in women, the pre-503
vailing view has been that this difference is due to504
the fact that women live longer than men on average,505
and older age is the greatest risk factor for AD. Many506
studies of incidence of AD have found no significant507
difference between men and women in the proportion508
who develop AD at any given age [129].
Biomarkers 509
Magnetic resonance imaging (MRI) studies show 510
that younger-onset patients have greater general- 511
ized neocortical atrophy than LOAD subjects when 512
compared to healthy controls [118, 130]. This is 513
in accordance with glucose metabolism studies, 514
which demonstrate a premature decline in glucose 515
metabolism and a more severe and widespread 516
hypometabolism in EOAD [131]. Regarding regional 517
differences, older patients tend to have a more circum- 518
scribed involvement, with preferential reduction in 519
the hippocampus and related structures, including the 520
amygdala [132] and retrosplenial and temporopari- 521
etal junction volumes [130], while younger patients 522
tend to have a greater temporoparietal and parietooc- 523
cipital grey matter atrophy [115, 120]. White matter 524
atrophymimics thispattern[133].Moreover,bothper- 525
fusion and glucose metabolism studies have shown 526
a predilection for temporo-parietal-occipital associ- 527
ation areas in EOAD versus medial temporal cortex 528
susceptibility in LOAD [119, 134]. Interestingly, 529
another study has shown no significant difference in 530
total or regional amyloid burden, measured by Pitts- 531
burg compound-B PET, despite showing decreased 532
glucose metabolism in bilateral temporoparietal and 533
occipital cortex in EOAD. This finding suggests that 534
both early A and increased susceptibility to pathol- 535
ogy in younger onset patients might be responsible 536
for cortical dysfunction in EOAD [135]. The greater 537
involvement of hippocampal-related structures in 538
LOAD is also apparent in functional connectivity 539
studies that have shown that older patients have 540
decreasedactivationof theanteromedial temporalnet- 541
work, correlatingwithpoorerperformance inmemory 542
tasks; EOAD was associated with less activation of the 543
dorsolateral prefrontal network, manifested by worse 544
performance on executive function tasks [118]. 545
CSF pathophysiological markers for AD include 546
decrease levels of A1–42 and increase levels of 547
total tau and hyperphosphorylated tau. The use of 548
these biomarkers combined is associated with sig- 549
nificant sensitivity and specificity in the diagnosis 550
of AD [136]. There is some evidence that EOAD 551
patients have a greater reduction of A1-42 (and 552
corresponding greater elevation of tau) than LOAD 553
patients when compared to young and old controls, 554
respectively, although no differences emerge in the 555
direct comparison between EOAD and LOAD [137]. 556
Others have reported lower levels of A1-42 in EOAD 557
[138] or no differences [120, 139]. A study compar- 558
ing CSF biomarkers along different EOAD subtypes, 559
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including amnestic, logopenic progressive aphasia560
and posterior cortical atrophy found no differences in561
the A levels, but showed that posterior cortical atro-562
phy had lower levels of total tau and phosphorylated563
tau [140].564
Genetics565
Amyloid precursor protein, presenilin 1, and pre-566
senilin 2 mutations can cause autosomal dominant567
AD, and although they may be present in up 71%568
of familial cases, they account for only about 1–5%569
of all AD patients. These patients typically have an570
early or very early-onset disease (<45 years) [136,571
141, 142]. A well-recognized genetic risk factor for572
AD is the APOE 4 allele. It is usually associated573
with greater hippocampal atrophy and a poorer per-574
formance in memory based tasks [121, 142] and it575
decreases the age of onset by up to 2.45 years for576
each copy of the allele [142, 143]. Conversely, non-577
APOE 4 patients tend to have greater structural and578
clinical involvement of non-hippocampal, neocorti-579
cal areas [121]. ApoE 4 allele carriers among AD580
patients are most frequently found in the 60–69-year-581
old range [144], therefore including both older EOAD582
patients and younger LOAD patients. The ApoE 2583
allele is less frequently found in AD patients than in584
normal controls and there seems to be no difference585
in its prevalence between EOAD and LOAD [144].586
Genome wide association studies have identified sev-587
eral other risk genes for LOAD. The association588
between nine of them (PICALM, CLU, CR1, BIN1,589
CD2AP, EPHA1, MS4A4A, CD33, and ABCA7) has590
been shown to account for 1.1% of age of onset vari-591
ation, versus 3.9% of variation provided by ApoE.592
The most significant association was found for the593
CR1, BIN1, and PICALM genes [143]. Another can-594
didate gene that may have an impact on age of onset595
is DCHS2, a gene expressed in the cerebral cortex596
[145]. Yet, and surprisingly, these genetic variants do597
not seem to bring significant value for the distinction598
between EOAD and LOAD, as they simply seem to599
anticipate pathology.600
INTERPLAY BETWEEN BRAIN AGING,601
NEUROINFLAMMATION, AND AD602
PHENOTYPES603
AD prevalence is strongly associated with increas-604
ing age and aging changes in microglia have been605
hypothesized to play a prominent role in disease606
pathogenesis [60]. Recently, the consistent pattern607
of increases in YKL-40 level with aging supports 608
the concept that neuroinflammation is a process that 609
occurs normally with aging [57–59]. The additional 610
finding of a stronger association with at-risk 4 611
carriers during mid middle age suggests that this age- 612
related process may be further exacerbated in the 613
presence of insults including amyloid deposition and 614
neuronal injury [59]. There are important clinical dif- 615
ferences between sporadic EOAD and LOAD. Taking 616
into account the data regarding the importance of 617
neuroinflammation in the pathogenesis of AD, par- 618
ticularly the role of microglia, and the differences 619
of the neuroimmunological milieu of the aged brain, 620
it is conceivable that the neuroinflammation associ- 621
ated to the AD can, at least in the beginning, differ 622
between these two groups and contribute for the clini- 623
cal differences. Not many studies have addressed this 624
issue. 625
Hoozemans et al. [146] compared the presence 626
of microglia and astrocytes, in clinically and patho- 627
logically confirmed AD and non-demented control 628
cases in relation to age. In their study they suggested 629
that the association between neuroinflammation and 630
AD is much stronger in relatively young patients as 631
compared to the older patients (age at death <80 ver- 632
sus >80 years old). Microglial activation increases 633
with the neuropathological stage and disease severity 634
[67, 85]. A key issue would be to know if inflamma- 635
tion differs between these two groups (EOAD versus 636
LOAD) at different pathological and clinically AD 637
stages. 638
Another remarkable finding is that, in contrast 639
to AD, activated microglia is not found in the 640
similar-appearing A diffuse deposits of the brains of 641
neurologically normal elderly individuals [147]. One 642
of the possibilities is that for those unusual elderly 643
individuals with only diffuse A deposits there is an 644
inherent difference in the responsiveness of microglia 645
[86]. Interestingly, plaque-associated microglia were 646
not seen in diffuse plaque-only young Down’s syn- 647
drome brain [148]. This subgroup of cases was from 648
very young patients (between 12 and 29 years old), 649
possible supporting the notion that A inflammatory 650
response can also differ in the very young. More 651
recently, a study showed that in Down’s syndrome 652
patients with AD pathology (>40 years old), there is 653
a distinct neuroinflammatory phenotype compared to 654
sporadic AD due to microglia bias toward an M2b 655
phenotype [149]. Clinicopathological studies from 656
brain donation programs showed that the presence of 657
moderate and severe AD type pathology changes is 658
more associated to dementia in younger old persons 659
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than in older old persons [150]. These findings sug-660
gest that additional factors are involved in the clinical661
expression of dementia in the oldest old, such as vari-662
able tolerance to neuropathological lesions [150]. We663
speculate that different neuroinflammation apparatus664
in this age can partial explain this discrepancy.665
The study of inflammatory cytokines in CSF as666
biomarkers of AD has shown very different and con-667
tradictory results between different research groups668
[89]. The analysis of different neuroinflammation-669
related proteins in the blood, including several670
interleukines (IL-1, Il-1, IL-6, IL-10), 2-671
macroglobulin, brain-derived neurotrophic factor672
(BDNF), complement factor H, and heat shock pro-673
tein 90 (Hsp90) has not shown significant differences674
between EOAD and LOAD, but studies are scarce and675
with small samples [151, 152]. TNF levels have676
been shown to be both higher and lower in EOAD677
[152, 153].678
Some of the risk loci in modifying age of disease679
onset identified in genome wide association stud-680
ies have recognized roles in the immune system,681
including phagocytosis and immune cell traffick-682
ing [154]. Both CLU and CR1 encode for proteins683
that regulate complement activation; EPHA1, mostly684
expressed in leukocytes, is involved in T cell regula-685
tion; ABCA7 is highly expressed in the hippocampal686
neurons and in microglia and is involved in A pro-687
cessing; and CD33, overexpressed in AD patient’s688
microglia, encodes for an endocytic receptor that689
takes part in cell-cell interactions and in immune cell690
regulation [154, 155]. TREM2, another loci associ-691
ated to increase risk for AD identified, is involved692
in immune response [75]. There are studies that693
found a significantly earlier symptom of onset in694
patients with TREM2 variants [156], but others found695
only an association to shortened disease duration696
and not to age of onset [76]. A cerebral amyloid697
angiopathy (CAA) and particularly A related angi-698
itis (ABRA), is other AD related clinical feature that699
bridges AD, inflammation and age. CAA describes a700
group of biochemically and genetically diverse dis-701
orders, which have in common the deposition of702
amyloid in media and adventitia of cortical and lep-703
tomeningeal vessels [157]. Sporadic CAA and AD704
have overlapping biology with shared risk factors705
[158]. A vascular deposition affects about 30% of706
the otherwise normal elderly and over 90% of those707
with AD, in whom CAA tends also to be more severe708
[157, 159]. ABRA is characterized by a vasculitic709
transmural, often granulomatous, inflammatory infil-710
trates affecting leptomeningeal and cortical vessels711
Fig. 2. Diagram illustrating age associated microglia dynamics
and temporal Alzheimer’s disease onset. Arrows exemplify two
time points for the beginning of AD biomarkers [A accumulation
(CSF/PET), sequentially followed by tau-mediated neuronal injury
(CSF)] at the preclinical stage.
that have abundant A deposition within the vessel 712
walls [159, 160]. The recent finding of autoantibod- 713
ies against A1-40 and A1-42 forms of amyloid in 714
the CSF of two patients with ABRA and inflamma- 715
tion associated to CAA [161, 162], together with the 716
description of meningoencephalitis caused by active 717
or passive immunotherapeutic approaches to reduce 718
A burden in AD [163], suggests that an immune 719
response directed against A may represent a com- 720
mon disease mechanism shared by ABRA and in 721
complications of therapy for AD [160]. The mean 722
age of presentation of ABRA is lower than that 723
of sporadic non-inflammatory A-related CAA (66 724
versus 76 years, respectively) [159, 160]. These find- 725
ings support a role for the interactions between age, 726
and inflammation in AD related pathophysiology and 727
clinical expression. 728
In summary, the pathophysiological mechanisms 729
underlying the clinical differences between EOAD 730
and LOAD are still not well known, but the dif- 731
ferences of neuroinflammation characteristics with 732
aging can help to partially explain it (Fig. 2). 733
CONCLUSION 734
Understanding both sides of microglial and astro- 735
cytosis inflammation process at functional and 736
molecular level will be necessary for the development 737
of treatment strategies for AD and aging [12]. 738
Additionally, the study of this delicate balance in 739
the different ages of onset of AD would be important 740
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to understand treatment efficacy in clinical trials and741
eventually, not only direct treatment to early disease742
stages, but also the possibility of establishing differ-743
ent treatment approaches in light of the age of the744
patient. The boost on AD diagnostic biomarkers will745
increase diagnostic certainty in life for the diagno-746
sis of dementia with AD pathology. This refinement747
will allow the increased recognition of the more748
often atypical clinical presentations in EOAD and749
thus increase the knowledge (epidemiology, clinical750
progression, biomarkers studies, neuroinflammation751
associated process, etc.) for a possible better under-752
standing of this complex disorder.753
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